FDA Clears CU Anschutz Clinical Trial Using Engineered Immune Cells to Fight Colorectal Cancer

Markets PR Newswire By PR Newswire 10 Sep 2026 19:15 1 min read
FDA Clears CU Anschutz Clinical Trial Using Engineered Immune Cells to Fight Colorectal Cancer

CAR T-cells developed at CU Anschutz will target two pathways that help colorectal tumors grow and evade the immune system AURORA, Colo., Sept. 10, 2026 /PRNewswire/ -- The U.S. Food and Drug Administration has granted permission for investigators at the University of Colorado Anschutz to...

Covered in this story

Read the full story on PR Newswire → Opens the original article on www.prnewswire.com

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.